128 related articles for article (PubMed ID: 32452349)
1. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
Fonti GL; Chimenti MS; Greco E; Boffa L; Conigliaro P; Triggianese P; Perricone R
Clin Exp Rheumatol; 2021; 39(1):223. PubMed ID: 32452349
[No Abstract] [Full Text] [Related]
2. Reply to: Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
Macaluso F; Guggino G; Ciccia F
Clin Exp Rheumatol; 2021; 39(1):224. PubMed ID: 32452343
[No Abstract] [Full Text] [Related]
3. Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis - A novel approach.
Nisar MK
Biologicals; 2019 Jul; 60():93-94. PubMed ID: 31204079
[No Abstract] [Full Text] [Related]
4. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis.
Macaluso F; Guggino G; Mauro D; Rizzo C; Bignone R; Ciccia F
Clin Exp Rheumatol; 2019; 37(6):1096. PubMed ID: 31287406
[No Abstract] [Full Text] [Related]
5. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Baeten D; Baraliakos X; Braun J; Sieper J; Emery P; van der Heijde D; McInnes I; van Laar JM; Landewé R; Wordsworth P; Wollenhaupt J; Kellner H; Paramarta J; Wei J; Brachat A; Bek S; Laurent D; Li Y; Wang YA; Bertolino AP; Gsteiger S; Wright AM; Hueber W
Lancet; 2013 Nov; 382(9906):1705-13. PubMed ID: 24035250
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases.
Cortese A; Lucchetti R; Altobelli A; Conte A; Primavera M; Valesini G; Millefiorini E; Scrivo R
Mult Scler Relat Disord; 2019 Oct; 35():193-195. PubMed ID: 31398658
[TBL] [Abstract][Full Text] [Related]
7. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective.
Kim D; Kim H; Cho S; Park MC
Int J Rheum Dis; 2019 Sep; 22(9):1630-1637. PubMed ID: 31215166
[TBL] [Abstract][Full Text] [Related]
8. [Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab].
Toussirot E; Salard D; Algros MP; Aubin F
Ann Dermatol Venereol; 2013 Dec; 140(12):801-2. PubMed ID: 24315228
[No Abstract] [Full Text] [Related]
9. Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1.
Tseng JC; Wei JC; Deodhar A; Martin R; Porter B; McCreddin S; Talloczy Z
Front Immunol; 2020; 11():561748. PubMed ID: 33324394
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab treatment for ankylosing spondylitis and concomitant Huntington's disease: real-world experience.
Bulut Gökten D; Mercan R
Clin Exp Rheumatol; 2024 Mar; 42(3):767. PubMed ID: 37877409
[No Abstract] [Full Text] [Related]
11. Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath.
Williams T; Wadeley A; Bond D; Cavill C; Freeth M; Sengupta R
Clin Rheumatol; 2020 May; 39(5):1501-1504. PubMed ID: 31989323
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of secukinumab 75 mg, 150 mg, and 300 mg in patients with active ankylosing spondylitis.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2021 Sep; 59(9):610-617. PubMed ID: 33993905
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.
Katsevman GA; Mariscal G; Barrios C; Domenech-Fernández P; Ziembinski C; Bhatia S
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):160-166. PubMed ID: 33001775
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review.
Eksin MA; Erden A; Güven SC; Armagan B; Ozdemir B; Karakas O; Omma A; Kucuksahin O
Immunotherapy; 2022 Apr; 14(6):401-408. PubMed ID: 35152720
[No Abstract] [Full Text] [Related]
15. Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study.
Deodhar A; Chakravarty SD; Shiff NJ; Lo KH; Xu S; Hsia EC; Danve A; Reveille JD
J Clin Rheumatol; 2022 Dec; 28(8):420-423. PubMed ID: 35649533
[No Abstract] [Full Text] [Related]
16. Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers.
Lo Nigro A; Ramonda R; Alaibac M; Modesti V; Punzi L
Eur J Dermatol; 2011; 21(2):263-4. PubMed ID: 21411412
[No Abstract] [Full Text] [Related]
17. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
Braun J; Baraliakos X; Deodhar A; Poddubnyy D; Emery P; Delicha EM; Talloczy Z; Porter B
Rheumatology (Oxford); 2019 May; 58(5):859-868. PubMed ID: 30590813
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series.
Apaydin H; Dogan I; Erten Ş
Int J Rheum Dis; 2020 Mar; 23(3):454-456. PubMed ID: 31945270
[No Abstract] [Full Text] [Related]
19. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
Baraliakos X; Braun J; Deodhar A; Poddubnyy D; Kivitz A; Tahir H; Van den Bosch F; Delicha EM; Talloczy Z; Fierlinger A
RMD Open; 2019; 5(2):e001005. PubMed ID: 31565244
[TBL] [Abstract][Full Text] [Related]
20. Effect of secukinumab on bone formation markers in patients with active ankylosing spondylitis.
Sakellariou GT; Konsta M; Katsigianni I; Deligeorgakis D; Zisopoulos D; Vounotrypidis P
Int J Rheum Dis; 2023 Dec; 26(12):2603-2606. PubMed ID: 37432022
[No Abstract] [Full Text] [Related]
[Next] [New Search]
